Effects of actinomycin D and cycloheximide on zinc status in marginally zinc-deficient rats

Biol Trace Elem Res. 2012 May;146(2):207-12. doi: 10.1007/s12011-011-9236-1. Epub 2011 Oct 25.

Abstract

During deficient zinc intake, rats are liable to suffer zinc deficiency under the following conditions: higher protein diet, diet containing higher quality (higher nutritive value) protein, and higher dietary intake. This suggests that a higher protein nutritional status (rapid increase in body protein) in rats leads to a lower zinc nutritional status (higher zinc requirement). In contrast, it is expected that a lower protein nutritional status (lowered body protein biosynthesis) is not liable to result in a lower zinc nutritional status. Therefore, the effects of protein biosynthesis inhibitors on zinc status were studied. Actinomycin D and cycloheximide were administered to rats under a marginally zinc-deficient condition. The growth of rats was depressed and serum and femur zinc concentrations were increased by administration of protein biosynthesis inhibitors. The carcasses of rats administered protein synthesis inhibitors had a higher zinc/protein ratio than those of the respective pair-fed (calorically equivalent to the zinc-deficient group) rats. Results suggest that zinc deficiency in rats is mainly alleviated by decreased food intake with administration of protein synthesis inhibitors. Furthermore, protein biosynthesis inhibition alone alleviated zinc deficiency.

MeSH terms

  • Alkaline Phosphatase / blood
  • Animal Nutritional Physiological Phenomena
  • Animals
  • Body Weight / drug effects
  • Cycloheximide / pharmacology*
  • Dactinomycin / pharmacology*
  • Dietary Proteins / administration & dosage
  • Dietary Proteins / pharmacology
  • Eating / drug effects
  • Femur / drug effects
  • Femur / metabolism
  • Male
  • Protein Synthesis Inhibitors / pharmacology
  • Rats
  • Rats, Wistar
  • Zinc / blood
  • Zinc / deficiency
  • Zinc / metabolism*

Substances

  • Dietary Proteins
  • Protein Synthesis Inhibitors
  • Dactinomycin
  • Cycloheximide
  • Alkaline Phosphatase
  • Zinc